Celgene Turns in Bulletproof Third-Quarter Earnings

Revlimid led Celgene Corp.'s lineup of third-quarter product revenues with $970 million in sales, divided nearly equally between U.S. and international sales. Abraxane, Vidaza and Thalomid also racked up healthy sales, bringing the Summit, N.J.-based pharma company to $1.419 billion in total revenue for the third quarter, a 14 percent increase over the same period in 2011.